Document:

Exhibit
10.13

 

Pursuant
to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit
because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

 

 

 

EXCLUSIVE
LICENSE AGREEMENT

 

between

 

EMORY
UNIVERSITY,

 

CHILDREN’S
HEALTHCARE OF ATLANTA, INC., 

 

UAB
RESEARCH FOUNDATION, 

 

and

 

Incysus,
LTD.

 

     

     

    

 

TABLE OF
CONTENTS

 

	ARTICLE
    1.	DEFINITIONS	3
	ARTICLE
    2.	GRANT
    OF LICENSE	8
	ARTICLE
    3.	CONSIDERATION
    FOR LICENSE	11
	ARTICLE
    4.	REPORTS
    AND ACCOUNTING	13
	ARTICLE
    5.	PAYMENTS	14
	ARTICLE
    6.	DILIGENCE
    AND COMMERCIALIZATION	15
	ARTICLE
    7.	PATENT
    PROSECUTION	16
	ARTICLE
    8.	INFRINGEMENT	17
	ARTICLE
    9.	LIMITED
    WARRANTY AND EXCLUSION OF WARRANTIES	18
	ARTICLE
    10.	DAMAGES,
    INDEMNIFICATION AND INSURANCE	19
	ARTICLE
    11.	CONFIDENTIALITY	21
	ARTICLE
    12.	TERM
    AND TERMINATION	22
	ARTICLE
    13.	ASSIGNMENT	24
	ARTICLE
    14.	ARBITRATION	24
	ARTICLE
    15.	MISCELLANEOUS	25
	ARTICLE
    16.	NOTICES	27
	APPENDIX
    A	COMPANY’S
    DEVELOPMENT PLAN	34
	APPENDIX
    B	LICENSED
    PATENTS	35
	APPENDIX
    C	U.S.
    GOVERNMENT LICENSE(S)	36
	APPENDIX
    D	RUNNING
    ROYALTY PERCENTAGES	37
	APPENDIX
    E	MINIMUM
    ROYALTIES	38
	APPENDIX
    F	MILESTONE
    PAYMENTS	39
	APPENDIX
    G	LICENSE
    MAINTENANCE FEES	40
	APPENDIX
    H	DEVELOPMENT
    MILESTONES AND DATES	41

 

     

     

    

 

THIS EXCLUSIVE LICENSE AGREEMENT
is made and entered into as of the 10th day of June, 2016, (hereinafter referred to as the “Effective Date”)
by and between EMORY UNIVERSITY, a nonprofit Georgia corporation with offices located at 1599 Clifton Road NE, 4th Floor,
Mailstop 1599/001/1AZ Atlanta, Georgia 30322, (hereinafter referred to as "EMORY"), CHILDREN’S HEALTHCARE
OF ATLANTA, INC., a Georgia nonprofit corporation with principal offices located at 1600 Tullie Circle, NE, Atlanta, GA 30329,
(hereinafter referred to as “CHILDREN’S”), The UAB Research Foundation, a non-profit 501(c)(3) corporation
incorporated in the State of Alabama with principal offices located at 701 20th Street South, AB 770, Birmingham, AL
35233 (hereinafter referred to as “UABRF”), and Incysus, Ltd., a corporation having a principal place of business
located at Clarendon House, 2 Church Street, Hamilton, HM11 Bermuda (hereinafter referred to as "COMPANY").

 

WHEREAS, EMORY, CHILDREN’S
and UABRF, (hereinafter together, “LICENSOR”) are the owners of all right, title, and interest in inventions
and technology, developed by their respective employees and are responsible for their protection and commercial development; and

 

WHEREAS, CHILDREN’S
is a joint owner with EMORY in inventions and technology, developed by certain employees of EMORY; and

 

WHEREAS, LICENSOR has developed certain
inventions and technology related to “[*****]” and “[*****],” which is in part described in EMORY File
Nos. [*****] and UABRF Case Nos. [*****]; and

 

WHEREAS, EMORY has entered into an
agreement with UABRF whereby EMORY takes the lead in seeking, negotiating and administering licenses to certain Licensed
Technology; and

 

WHEREAS, EMORY has entered into an
agreement with CHILDREN’S whereby EMORY may take the lead in seeking, negotiating and administering licenses
to the Licensed Technology; and

 

WHEREAS, COMPANY wishes to
obtain and LICENSOR wishes to grant certain rights to pursue the development and commercialization of the Licensed Technology
in accordance with the terms and conditions of the Agreement;

 

NOW, THEREFORE, for and in consideration
of the mutual covenants and the premises herein, the parties, intending to be legally bound, hereby agree as follows.

 

Article
1.        DEFINITIONS

 

The following terms as used herein shall
have the following meaning:

 

"Affiliate"
shall mean any corporation or non-corporate business entity which controls, is controlled by, or is under common control with
a party to this Agreement. A corporation or non-corporate business entity shall be regarded as in control of another
corporation if it owns, or directly or indirectly controls, at least fifty (50%) percent of the voting stock of the other
corporation, or if it possesses, directly or indirectly, the power to direct or cause the direction of the management and
policies of such entity.

 

    3 

     

    

 

"Agreement"
or "License Agreement" shall mean this Agreement, including all APPENDICES.

 

“COMPANY’s Development
Plan” shall mean the plan detailed in APPENDIX A of this Agreement, which may be amended upon written agreement
by the parties.

 

"Dollars" shall
mean United States dollars.

 

"Field of Use"
shall mean all fields.

 

"Indemnitees"
shall mean the Inventors and their respective heirs, executors, administrators and legal representatives and each of EMORY, CHILDREN’S,
UABRF, their Affiliates, their trustees, directors, officers, employees, agents, contractors, and students, successors and legal
representatives.

 

“Inventors”
shall mean the inventors of the Licensed Patents.

 

"Licensed Patents"
shall mean the patents and/or patent applications identified in APPENDIX B, together with any and all substitutions, extensions,
divisionals, continuations, continuations-in-part (to the extent that the claimed subject matter of such continuations-in-part
is disclosed in the parent License Patent and rights to the continuations-in-part are not obligated to a third party), foreign
counterparts of such patent applications and any patents which issue thereon anywhere in the world, including reexamined and reissued
patents.

 

"Licensed Product(s)"
shall mean any process, service or product covered by a Valid Claim of any Licensed Patent or that incorporates or uses any Licensed
Technology. For the avoidance of doubt, a process, service or product is a Licensed Product if it incorporates Licensed Technology
and adds additional features.

 

"Licensed Know-How" shall mean tangible and
intangible technical information found in research notebooks, folders, e-files (CDs, diskettes, tape, hard drives, external drives,
third-party note taking applications, cloud and flash storage) containing the researchers and/or inventors’ work related
to the Licensed Patents including but not limited to:

 

    4 

     

    

 

Preclinical

 

Materials, methods, techniques and observations
related to:

 

		a)	Preclinical animal efficacy and toxicity data
		b)	Viral transduction of immune effector cells
		c)	Generation of chemotherapy resistant immune effector cells
		d)	Transducing CARs into immune effector cells

 

Regulatory

 

Pre-IDE briefing documents

Pre-IDE meeting submission
and minutes

IDE application/submission

IDE approval

Pre-IND briefing documents
(if any)

Pre-IND submission

Pre-IND meeting notes

Pre-IND meeting minutes

IND submission

IND meeting notes and minutes

IND correspondence and approvals

Any regulatory correspondence,
submissions, requests for meeting, minutes and approval of protocol changes

All IRB submissions, comments,
revisions and resubmissions (if any) related to clinical trials

 

CMC

 

Manufacturing SOPs/Protocols related to CMC

 

		a)	Manufacturing SOPs/Protocols for CMC for single and multi-site cross validation
		b)	All analytical data and analysis performed in preparation for CMC submission, including data for validation and qualification
of assays
		c)	All third party contracts and correspondence including, data, SOPs, and analysis generated in preparation for CMC submission
(e.g., CROs that contributed mycobacterial analysis, mass spec, viral contamination analysis etc.)
		d)	Most recent Pharm/Tox data updates
		e)	Any data and analysis prepared for CMC filing, including third party contractors
		f)	Regulatory documents related to anticipated CMC filings

 

    5 

     

    

 

Clinical

 

Draft Clinical trial protocol(s)

Final Clinical trial protocol(s)

Statistical design(s) and protocols
for clinical trials

Any minutes/submissions/correspondence
from CRTC (Cancer center Translational Research Committee) meeting

Any minutes/submissions/correspondence
from NIH RAC

Any minutes/submissions/correspondence
from Brain Tumor Working Group

Copies of all grants and grant
applications that funded the research and clinical studies

All existing manuscripts in
preparation or submission covering the research or clinical studies

Any pharmacy reports related
to study drug shipping, handling, and distribution to investigators, including pharmacy contacts at each clinical site

 

Contact information for study
participants, including but not limited to investigators, scientific advisors, statisticians, nurse coordinators, quality and regulatory
personnel.

 

Any interim and final results
from clinical studies including:

 

		a)	Current patient responses and disease free survival, including follow up data and chart entries to verify response and survival

		b)	Redacted patient case record forms (CRFs), lab tests, CT’s, Pet scans,

		c)	Most recent Pharm/Tox data and patient safety updates, and

 

(collectively, “Know-How”), which are
known, learned, invented, or developed solely by the Inventors and disclosed to LICENSOR by the Inventors as of the Effective Date
to the extent that (i) in the reasonable judgment of COMPANY and LICENSOR, such Know-How is required for the manufacture, use,
development, testing, marketing, export, import, offer for sale or sale of any Licensed Product and (ii) LICENSOR possesses the
right to license the use of such Know-How to COMPANY for commercial purposes.

 

“Licensed Technology”
means Licensed Patents and Licensed Know-How.

 

"Licensed Territory"
means the world.

 

"Net Selling Price"
of Licensed Products shall mean the gross selling price paid by a purchaser of a Licensed Product to COMPANY, an Affiliate or Sublicensee
of COMPANY, or any other party authorized by COMPANY to sell Licensed Products less the following discounts:

 

		a)	customary trade, quantity and cash discounts actually allowed and taken, including rebates granted to managed health care or
governmental organizations;
		b)	credits actually given for retroactive price reductions, rejected or returned Licensed Products;
		c)	freight, postage, shipping, transportation and insurance costs, if actually paid and separately itemized on the invoice paid
by the purchaser; and
		d)	excise taxes, customs duties and other governmental charges included in the invoiced amount.

 

    6 

     

    

 

Where a Sale is deemed [*****]
of Licensed Products for other than a selling price stated in cash, the term "Net Selling Price" shall mean the average
gross selling price billed by COMPANY in consideration of the Sale of comparable Licensed Products during the [*****] period immediately
preceding such Sale, without [*****]. If no Sales of Licensed Products have occurred in the preceding [*****], then the parties
shall, in good faith, negotiate the cash value of such Sale. In the event that the parties cannot agree on the Net Selling Price
within [*****] of beginning such negotiations, the Net Selling Price shall be determined by a mutually agreeable qualified appraiser.

 

Notwithstanding the foregoing
in this Section, amounts received by COMPANY, its Affiliates or Sublicensees of COMPANY or its Affiliates for the sale of Licensed
Products among COMPANY, its Affiliates and Sublicensees for resale shall not be included in the computation of Net Selling Price
hereunder.

 

“Prosecution and Maintenance”
or “Prosecute and Maintain” shall mean, with respect to a particular patent application or patent, the preparation,
filing, prosecution and maintenance of such patent or patent application, as well as re-examinations, reissues, applications for
patent term extensions and the like with respect to such patent or patent application, together with the conduct of interferences,
the defense of oppositions and other similar proceedings with respect to such patent or patent application.

 

“Regulatory
Documents” means any document or information prepared for submission to, or submitted to any Governmental Authority with
respect to the Licensed Patents that have been provided to LICENSOR and/or an Inventor. Regulatory Documents shall include, but
not be limited to, documents related to investigational new drug applications.

 

"Sale," “Sell”
or "Sold" shall mean the sale, transfer, exchange, or other disposition of Licensed Products whether by gift or
otherwise by COMPANY, its Affiliates, Sublicensees or any third party authorized by COMPANY to make such sale, transfer, exchange
or disposition. Sales of Licensed Products shall be deemed consummated upon the first to occur of: (a) receipt of payment from
the purchaser; (b) delivery of Licensed Products to the purchaser or a common carrier; (c) release of Licensed Products from consignment;
(d) if deemed Sold by use, when first put to such use; or (e) if otherwise transferred, exchanged, gifted, or disposed of, when
such transfer, exchange, gift, or other disposition occurs.

 

    7 

     

    

 

To the extent that a Licensed
Product is provided for a Humanitarian Purpose or is distributed under an Investigational New Drug Application (“IND”)
or its domestic or foreign equivalent, the distribution will not be considered a Sale if the Net Selling Price does not exceed
the Absorbed Cost thereof. Licensed Product distributed for a “Humanitarian Purpose” shall mean: 1) distribution through
programs providing Licensed Product to government agencies or not-for-profit organizations established for charitable, humanitarian,
or educational purposes such as organizations classified by the Internal Revenue Service under 501(c)(3) or (4),or any national
or international equivalent thereof; and 2) distribution through programs providing Licensed Products to individual physicians,
pharmacies or patients in countries that are listed, at the time of first sale of any Licensed Product by
the World Bank, as a low or low middle income country which are listed in attached APPENDIX I. If the actual Net
Selling Price of products distributed for a Humanitarian Purpose or under an IND exceeds the Absorbed Costs, the distribution shall
be deemed to be a Sale. For these purposes, “Absorbed Costs” shall mean the amounts allocated by COMPANY for
distribution of a Licensed Product calculated in accordance with reasonable cost accounting methods consistent with the way COMPANY
allocates such costs to other products and which shall be calculated from: (i) direct labor used in support of manufacturing operations;
(ii) materials; (iii) overhead costs including facility and administrative expenses; and (iv) reasonable third party costs.

 

"U.S. Government Licenses"
shall mean the non-exclusive license to the U.S. Government or agencies thereof pursuant to NIH grant No.: [*****], copies of which
are attached hereto as APPENDIX C.

 

"Valid Claim"
shall mean a claim in an unexpired patent or pending patent application so long as such claim shall not have been irrevocably abandoned
or held invalid in an unappealable decision of a court or other authority of competent jurisdiction in the relevant country.

 

Article
2.     GRANT OF LICENSE

 

2.1       License.
LICENSOR hereby grants COMPANY and its Affiliates an exclusive, sublicenseable right and license, subject to Sections 2.2
through 2.6, in and to the Licensed Patents to make, have made, use, advance, manufacture, have manufactured, commercialize,
have commercialized, use, have used, import, export, rent, lease, distribute, offer for sale, and sell, or have sold Licensed
Products in the Field of Use in the Licensed Territory during the term of this Agreement. LICENSOR hereby grants COMPANY and
its Affiliates an exclusive right and license, subject to Sections 2.2 through 2.7 in
and to their interest in the Licensed Know-How to develop, have developed, make, have made, advance, manufacture, have
manufactured, commercialize, use, have used, import, export, rent, lease, distribute, offer for sale, and sell, or have sold
Licensed Products in the Field of Use in the Licensed Territory during the term of this Agreement. LICENSOR shall use
reasonable efforts to transfer or provide to COMPANY a copy of Licensed Know-How requested by the COMPANY, which has not been
previously provided, within [*****] of any written request. LICENSOR shall use reasonable efforts to transfer or provide to
COMPANY a copy of all Regulatory Documents (i) within [*****] of LICENSOR’s receipt of such from the Inventors or (ii)
within [*****] of the submission or receipt of such Regulatory Documents by LICENSOR, whichever shall occur first. For the
avoidance of doubt, LICENSOR shall promptly after the Effective Date transfer to COMPANY a copy any investigational new drug
application related to any Licensed Patent.

 

    8 

     

    

 

2.2     Government
Rights. COMPANY acknowledges that LICENSOR and COMPANY may have certain obligations and the United States government may have
certain rights in the Licensed Technology if such was developed with any assistance through grants or contracts from the United
States. COMPANY hereby warrants that it shall take all action necessary to satisfy and to enable LICENSOR to satisfy such obligations.
If the United States government should take action which [*****], LICENSOR or COMPANY may [*****] upon reasonable prior notice
or [*****] upon reasonable prior notice to [*****] (including without limitation with respect to [*****]). LICENSOR will provide
reasonable prior notice to enable COMPANY to [*****]. COMPANY shall [*****] prior to the date of such action.

 

2.3     Research
Agreement. In the event COMPANY or its Affiliates wish to conduct research on the Licensed Patents or any Licensed Product
with Inventors or LICENSOR, this research will be the subject of a separate research collaboration agreement between EMORY, UABRF,
or CHILDREN’S (as applicable) and COMPANY to be negotiated in good faith by the relevant Parties.

 

2.4     Retained
License. The exclusive license granted herein is further conditional on the right retained by LICENSOR, on behalf of themselves,
their employees and research collaborators, to make, have made, use, import, and transfer Licensed Products and practice the Licensed
Technology for non-commercial research, educational and non-commercial and humanitarian clinical purposes.

 

2.5     Sublicenses.
Upon written approval from EMORY, on behalf of LICENSOR, such approval not to be unreasonably withheld, COMPANY may grant
sublicenses to third parties (“Sublicensees”) with financial terms and conditions that are at least as
favorable to LICENSOR and that are consistent with the other terms and conditions of this Agreement, provided that COMPANY
shall be responsible for the obligations of its Sublicensees that are relevant to this Agreement and remain responsible for
any reporting and any payment of all fees and royalties due under this Agreement. Subject to the sublicensing terms in this
Section 2.5, Sublicensees may be permitted to further sublicense their rights to practice the Licensed Patents. COMPANY shall
not enter into any sublicense without fully and completely complying with Section 15.1 herein.

 

2.5.1       COMPANY
shall include in any sublicense granted pursuant to this Agreement, a provision requiring the Sublicensee to indemnify Indemnitees
and maintain liability coverage to the same extent that COMPANY is so required pursuant to Section 10.3 of this Agreement.

 

    9 

     

    

 

2.5.2       COMPANY
shall include in any sublicense granted pursuant to this Agreement, a provision that grants EMORY the right to audit the Sublicensee
to the same extent that EMORY has the right to audit the COMPANY pursuant to Section 4.4 of this Agreement.

 

2.5.3       COMPANY
shall provide EMORY with copies of all sublicense agreements and any amendments and terminations within [*****] of their execution
date, which, if redacted, must include the relevant provisions under this Article 2 and [*****] terms of the sublicense; the disclosure
of sublicense agreements to EMORY shall be subject to the confidentiality obligations set forth in this agreement.

 

2.5.4       COMPANY
shall ensure that any sublicense or distributor agreements will include a provision that causes automatic termination of the sublicense
or distribution agreement in the event that a Sublicensee or distributor challenges, either directly or indirectly, the validity,
enforceability or scope of any claim within the Licensed Patents in a court or other governmental agency of competent jurisdiction,
including in a reexamination or opposition proceeding.

 

2.5.5       If
this Agreement terminates for any reason other than Expiration, (i) COMPANY shall notify the Sublicensee of the termination, (ii)
the sublicense will terminate simultaneously with the termination of this Agreement, and (iii) upon mutual agreement, the Sublicensee
may enter into a license agreement with LICENSOR with respect to the rights and terms originally sublicensed to it by COMPANY.

 

2.5.6       Subject
to the sublicensing terms in this Section 2.5, Sublicensees may be permitted, on a case-by-case basis, to further sublicense their
rights to practice the Licensed Patents.  Prior to the execution of any sublicense agreement which allows a Sublicensee to
further sublicense, COMPANY shall present to EMORY a reasonably detailed business justification for the proposed sublicense, as
well as [*****], for LICENSOR’s review and approval, such approval not to be unreasonably withheld.  COMPANY shall
proceed with execution of the proposed sublicense agreement only with EMORY’s prior written consent, such consent not to
be unreasonably withheld.

 

2.6     No Implied License. The license
and rights granted in this Agreement shall not be construed to confer any rights upon COMPANY, its Affiliates, or Sublicensees
by implication, estoppel, or otherwise as to any technology not specifically identified in this Agreement as Licensed Technology.

 

2.7     U.S.
Manufacturing. To the extent that any Licensed Technology is developed using any funding from the United States government,
COMPANY agrees to use its best efforts to substantially manufacture in the United States, any Licensed Products sold in the United
States unless any waivers required are obtained from the United States government. COMPANY shall notify EMORY if it desires to
request any such waivers, which request EMORY or UABRF (as applicable) shall make to the United States government on COMPANY’s
behalf.

 

    10 

     

    

 

Article
3.CONSIDERATION FOR LICENSE

 

3.1     License
Fee. As partial consideration for the license granted to COMPANY under this Agreement, COMPANY shall pay EMORY on behalf of
the LICENSOR a license fee in the amount of [*****] Dollars within [*****] of the Effective Date of this Agreement.

 

3.2     Running
Royalties. As partial consideration for the license granted to COMPANY under this Agreement, COMPANY shall pay EMORY on behalf
of the LICENSOR a total royalty equal to the percentage set forth on APPENDIX D times the Net Selling Price of all Licensed
Products Sold during the term of this Agreement by COMPANY, its Affiliates, its Sublicensees or any third party authorized by COMPANY
to Sell Licensed Products. Royalties shall be due and payable on a quarterly basis (March 31, June 30, September 30 and December
31) [*****] following the end of the calendar quarter in which such amounts were received by COMPANY.

 

3.2.1       Global
Access Sales. Notwithstanding the foregoing, COMPANY, its Affiliates or Sublicensees shall pay EMORY on behalf of the LICENSOR
[*****] total royalty on Net Sales of Licensed Products sold in a country that is listed, at the time of first sale of any Licensed
Product in any country, by the World Bank as a low or low middle income country or which is
listed in attached APPENDIX I, if the Net Selling Price of such Licensed Products exceeds the Absorbed Cost thereof. Should
the Net Selling Price of such Licensed Products not exceed the Absorbed Cost thereof, such sales shall be treated as Humanitarian
and no royalty shall be due.

 

3.2.2       Reduction
of Royalties-Third Party Royalties. If, at any time, COMPANY discovers that any Licensed Product or the use thereof in
the Field of Use or the practice of any Licensed Patent infringes claims of an unexpired patent or patents other than those
in the Licensed Patents, COMPANY may, if it has not already done so, negotiate with the owner of such patents for a license
on such terms as COMPANY deems appropriate. Should the license with the owner of such patents require the payment of
royalties or other consideration to such owner, then the royalties otherwise payable under this Agreement may be reduced by
the amount payable [*****] to the other patent owner(s). Notwithstanding
the foregoing, however, in no event shall the royalties due to EMORY on behalf of the LICENSOR on Net Sales of such Licensed
Products in any country be reduced by more than [*****] of the Running Royalty Percent as identified in APPENDIX D. If
a combination product incorporates a product based on a patent (other than a Licensed Patent) to which COMPANY has secured
rights via an agreement with the patent owner and the owner of such patent requires the payment of royalties or other
consideration to such owner, then the royalties otherwise payable under this Agreement may be reduced by the amount payable
[*****] to the other patent owner(s), but in no event shall the royalties payable under this Agreement be reduced by more
than [*****].

 

    11 

     

    

 

3.2.3      Minimum
Royalties. In the event that, following the first Sale of a Licensed Product (“First Sale”), the aggregate royalties
paid to EMORY on behalf of the LICENSOR during any calendar year pursuant to Section 3.2 hereof do not exceed the minimum royalty
set forth in APPENDIX E, COMPANY shall pay to EMORY on behalf of the LICENSOR no later than [*****] following the last day
of such calendar year the difference between such minimum royalty amount and the actual royalties paid.

 

3.3     Sublicensee
Payments. Within [*****] of receipt by COMPANY, COMPANY shall pay to EMORY on behalf of the LICENSOR as specified below, a
percentage of any fees or payments paid to COMPANY by a Sublicensee (“Sublicensee Percentage”) as consideration for
a sublicense grant under this Agreement. Such Sublicense Percentage shall be applied to any payments made to COMPANY by a Sublicensee,
including but not limited to any initial licensing fees, milestone fees, maintenance fees, and premium equity payments, to the
extent any such premium equity payment is directly attributable to the sublicense of the Licensed Patents and Licensed Technology.

 

	Percentage	Sublicense Executed
	15%	 Prior to completion of a Phase I clinical trial
	10%	 After completion of any Phase I clinical trial
	5%	After completion of any Phase II clinical trial
	2%	After completion of any Phase IIb clinical trial
	1%	 After completion of any Phase III clinical trial

 

For purposes of this Agreement, premium equity payments shall
mean the positive difference between the amount paid for COMPANY equity by a Sublicensee and the fair market value of said equity.
The fair market value shall be the amount paid in the last round of financing if within [*****], or, if no round of financing occurred
in that time, shall be agreed upon by the parties.

 

3.4     Milestone
Payments. COMPANY shall pay to EMORY on behalf of the LICENSOR a Milestone Payment in the amount specified in APPENDIX F
no later than [*****] after the occurrence of the corresponding Milestone Event. To the extent that a Milestone Payment is due
to the COMPANY from a Sublicensee, the COMPANY shall pay to EMORY on behalf of the LICENSOR the amount of the Milestone Payment
due.

 

3.5     License
Maintenance Fees. In the event no Milestone Payment has been paid to EMORY on behalf of the LICENSOR prior to an anniversary
of the Effective Date as set forth on APPENDIX G, COMPANY shall pay to EMORY on behalf of the LICENSOR the corresponding
Maintenance Fee. No Maintenance Fee pursuant to this Section 3.5 shall be payable by COMPANY in the event it has achieved at least
one Milestone Event and paid the corresponding Milestone Payment.

 

3.6     Reimbursement
for Patent Expenses.

 

3.6.1      COMPANY shall reimburse EMORY on behalf of the
LICENSOR for all fees, costs, and expenses incurred by EMORY and/or LICENSOR after the Effective Date and during the term of this
Agreement related to Prosecuting or Maintaining the Licensed Patents in the Licensed Territory. COMPANY shall deliver such payment
to EMORY on behalf of the LICENSOR within [*****] after EMORY on behalf of the LICENSOR provides COMPANY with detailed invoices
of the amount of such fees, costs, and expenses. To the extent that COMPANY does not remit payment of any uncontested amounts within
[*****] of notification, a late payment charge of [*****] will be assessed against the COMPANY.

 

3.6.2       COMPANY
shall reimburse EMORY on behalf of the LICENSOR for all fees, costs, and expenses incurred by LICENSOR as of the Effective Date
related to Prosecuting or Maintaining the Licensed Patents. These fees, costs, and expenses incurred up to the Effective Date are
estimated to be [*****], however this amount may be subject to reasonably change upon final notification to COMPANY. COMPANY shall
deliver such payment to EMORY on behalf of the LICENSOR the earlier of [*****] from the Effective Date or [*****] of the [*****]
and receipt by COMPANY of a detailed invoice of such costs.

 

3.7     Tax
Payments. All payments made to EMORY on behalf of the LICENSOR under this Agreement shall be made free and clear of any
tax, withholding or other governmental charge or levy (other than taxes imposed on the net income of LICENSOR), all such
non-excluded amounts being “Taxes.” Should the COMPANY be obligated by law to withhold any Taxes on such
payments, the payment due hereunder shall be increased such that after the withholding of the appropriate amount EMORY on
behalf of the LICENSOR receives the amount that would have been paid but for the Taxes withheld. Should LICENSOR be obligated
to pay such Taxes, and such Taxes were not satisfied by way of withholding, COMPANY shall promptly reimburse EMORY on behalf
of the LICENSOR for such payment, in an amount such that after the payment of the Taxes, LICENSOR has received the same
amount that it would have received had such Taxes not been payable.

 

    12 

     

    

 

Article
4.       REPORTS AND ACCOUNTING

 

4.1.    Progress
Reports. Within [*****] after [*****] of each calendar year, COMPANY shall provide EMORY on behalf of the LICENSOR with a written
report detailing the activities of the COMPANY relevant to the COMPANY’s Development Plan and the development and commercialization
of Licensed Products. For avoidance of doubt, non-receipt of such written report within the specified time period shall [*****].

 

4.2.    Royalty
Reports. Beginning [*****], during the term of this Agreement, COMPANY shall provide EMORY on behalf of the LICENSOR written
reports [*****] until the first Sale of a Licensed Product and quarterly thereafter showing:

 

		i.	the occurrence of any event triggering a Milestone Payment obligation or any other payment in accordance with Article 3;
		ii.	a summary of all reports provided to COMPANY by COMPANY'S Sublicensees, including the names and addresses of all Sublicensees;
		iii.	the amount of any consideration received by COMPANY from Sublicensees and an explanation of the contractual obligation satisfied
by such consideration;
		iv.	within a given fiscal quarter, the gross selling price and the number of units of all Licensed Products (identified by product
number/name) Sold in each country of the Licensed Territory, together with the calculations of Net Selling Price;
		v.	within a given fiscal quarter, the royalties payable in Dollars which accrued hereunder; and
		vi.	within a given fiscal quarter, the exchange rates, if any, used in determining the amount due.

 

4.3.    Records.
During the term of this Agreement and for a period of [*****] thereafter, COMPANY shall keep at its principal place of business
true and accurate records of all Sales in accordance with generally accepted accounting principles in the respective country where
such Sales occur and in such form and manner so that all royalties owed to EMORY on behalf of the LICENSOR may be readily and accurately
determined. COMPANY shall furnish EMORY on behalf of the LICENSOR copies of such records upon EMORY’s request.

 

    13 

     

    

 

4.4.    Right
to Audit. EMORY on behalf of the LICENSOR shall have the right, upon prior notice to COMPANY, its Affiliates or a Sublicensee,
not more than once in each [*****] period and the calendar year immediately following termination of the Agreement, through an
independent certified public accountant selected by EMORY on behalf of the LICENSOR, to have access during normal business hours
as may be reasonably necessary to examine the records of COMPANY, its Affiliates or Sublicensee to include, but not be limited
to, sales invoice registers, sales analysis reports, original invoices, inventory records, price lists, sublicense and distributor
agreements, accounting general ledgers, and sales tax returns, in order to verify the accuracy of the of the calculation of any
payment due under this Agreement. If such independent public accountant's report shows any underpayment of royalties by COMPANY,
its Affiliates or Sublicensees, within [*****] after COMPANY'S receipt of such report, COMPANY, or its Affiliates, shall remit
or shall cause its Sublicensees to remit to EMORY on behalf of the LICENSOR:

 

		(i)	the amount of such underpayment; and
		(ii)	if such underpayment exceeds [*****] percent of the total royalties owed for the fiscal year then being reviewed, the reasonably
necessary fees and expenses of such independent public accountant performing the audit.

 

Otherwise, EMORY's accountant's fees and
expenses shall be borne by LICENSOR in accordance with the terms of the agreements between EMORY and CHOA and EMORY and UABRF.

 

Article
5.       PAYMENTS

 

5.1.    Payment
Due Dates. Royalties shall accrue commencing upon the first Sale of a Licensed Product in the Licensed Field of Use in
any country in the Licensed Territory. Royalties and sublicense fees payable to EMORY on behalf of the LICENSOR as a result
of activities occurring during the period covered by each royalty report provided for under Article 4 of this Agreement shall
be due and payable on the date such royalty report is due. All other payments required under this Agreement, if not specified
otherwise in this Agreement, shall be payable within [*****] of the receipt by Company of payment or other due date of each
payment.

 

5.2.    Payment
Delivery. Unless otherwise requested by EMORY, all payments due to LICENSOR under this Agreement shall be made in person or
via the United States mail or private carrier to the following address:

 

Emory University

Attn: Director, Office of Technology Transfer

1599 Clifton Rd. 4th Floor

Atlanta, Georgia 30322

Facsimile: (404) 727-1271

 

Any payment in excess of [*****] dollars
or originating outside of the United States shall be made by wire transfer to an account of EMORY for and on behalf of LICENSOR
designated by EMORY from time to time and royalty reports shall be sent by facsimile or express courier to the Director, Office
of Technology Transfer on the same date. Royalty reports may also be transmitted via email to OTT-Legal@EMORY.edu, provided that
if no confirmation of receipt is received, COMPANY agrees to forward the report via facsimile or express courier.

 

5.3.    Currency
Conversion. Except as hereinafter provided in this Section 5.3, all royalties shall be paid in U.S. Dollars. If any Licensed
Products are Sold for consideration other than Dollars, the Net Selling Price of such Licensed Products shall first be determined
in the foreign currency of the country in which such Licensed Products are Sold and then converted to Dollars at a ninety (90)-day
trailing average published by the Wall Street Journal (U.S. editions), Bloomberg or equivalent for conversion of the foreign
currency into Dollars on the last day of the quarter for which such payment is due.

 

5.4.    Interest.
Royalties and other payments required to be paid by COMPANY pursuant to this Agreement shall, if overdue, bear interest until payment
at a rate [*****]. The interest payment shall be due from the day the original payment was due until the day that the payment was
received by EMORY. The payment of such interest shall not foreclose EMORY and/or LICENSOR from exercising any other rights it may
have because any payment is overdue. Should any overdue payment be collected through a third party service due to non-payment,
COMPANY agrees to pay any fees charged by such service in addition to any overdue delinquency.

 

    14 

     

    

 

Article
6.       DILIGENCE AND COMMERCIALIZATION

 

6.1.     Diligence.
COMPANY represents and warrants that it has the necessary expertise and will, as appropriate, acquire the necessary resources
to fully develop and commercialize Licensed Products. COMPANY shall use its best efforts, either directly or through
Affiliates or Sublicensees, throughout the term of this Agreement to comply with COMPANY's Development Plan and to bring
Licensed Products to market through a thorough, vigorous, and diligent program for exploitation of the rights and license
granted in this Agreement to COMPANY and to create, supply, and service in the Licensed Territory as extensive a market as
reasonably possible and shall include substantially similar diligence and commercialization terms in any sublicense
agreement. In no instance shall COMPANY's best efforts be less than efforts customary in COMPANY's industry for similar
technologies utilizing those resources that would be employed by COMPANY of a product or compound of similar market potential
at a similar stage in its development or product life as the Licensed Products (taking into account, without limitation,
issues of safety and efficacy, product profile, intellectual property situation, regulatory environment and other relevant
scientific and commercial factors). If EMORY on behalf of the LICENSOR reasonably determines that COMPANY is failing to meet
its diligence requirement for any particular Licensed Product, EMORY on behalf of the LICENSOR may, upon [*****] prior
written notice specifying the details of the suspected breach, terminate or partially terminate this Agreement and grant
third parties rights in the Licensed Technology, unless within such [*****] period, COMPANY can provide reasonable evidence
of meeting the requirements under this Agreement.

 

6.2.    Development
Milestones. COMPANY shall adhere to the schedule of development milestones and dates set forth in APPENDIX H. If COMPANY
fails to meet any deadline set forth in APPENDIX H, due to a failure to reasonably demonstrate sufficient diligence through
the expenditure of time, money or effort in planning, working and undertaking objectives in accordance with the Development Plan,
EMORY on behalf of the LICENSOR, may, upon [*****] prior written notice, terminate or partially terminate this Agreement and grant
third parties rights in the Licensed Patents and Licensed Technology unless COMPANY cures its failure within a [*****] remedy
period. If COMPANY fails to meet any deadline set forth in APPENDIX H and such failure is not attributable to [*****],
and COMPANY has reasonably demonstrated sufficient diligence [*****], then EMORY on behalf of the LICENSOR and COMPANY agree to
enter good-faith negotiations to adjust the development milestones. If, upon [*****] following the passing of a development milestone,
the parties are unable to reach agreement on restating the milestone deadlines, EMORY on behalf of the LICENSOR may terminate
or partially terminate this Agreement and grant third parties rights in the Licensed Patents and Licensed Technology. The Parties
acknowledge and agree that the Development Plan, and the development and commercialization milestones, each set forth on attached
Exhibits A and H, are reasonable. If, following the first adjustment of the development milestones, COMPANY fails to meet the
restated milestone deadlines and such failure is not attributable to [*****], then EMORY on behalf of the LICENSOR may, upon written
notice, terminate or partially terminate this Agreement and grant third parties rights in the Licensed Technology.

 

6.3.    Sublicensee
Performance. LICENSOR agrees that a Sublicensee’s or Affiliate’s performance of its diligence obligations regarding
a Licensed Product as set forth in the sublicense agreement shall be deemed to be performance by COMPANY of its diligence obligations
for such Licensed Product under this License Agreement, including, but not limited to, those set forth in Article 6 hereof. COMPANY
further agrees to attach copies of pertinent portions of this Agreement, as jointly redacted by COMPANY and EMORY, to executed
sublicense agreements and to provide a report on a Sublicensee’s performance as part of its reporting obligations under Article
4.

 

    15 

     

    

 

Article
7.      PATENT PROSECUTION

 

7.1.    Licensed
Patents. The Prosecution and Maintenance of the Licensed Patents shall be the primary responsibility of EMORY on behalf of
the LICENSOR. EMORY on behalf of the LICENSOR shall select such legal counsel as it deems appropriate to assist it in this process,
provided that such counsel is reasonably acceptable to COMPANY.

 

7.1.1       
Comment. EMORY on behalf of the LICENSOR shall provide COMPANY with copies of all filings and official correspondence pertaining
to such Prosecution and Maintenance of the Licensed Patents so as to give COMPANY an opportunity to advise and reasonably cooperate
with EMORY on behalf of the LICENSOR in such Prosecution and Maintenance. In the event LICENSOR desires to transfer the prosecution
of any of the Licensed Patents to new patent counsel, COMPANY’s written consent shall be obtained, which consent shall not
be unreasonably withheld or delayed.

 

7.1.2        New Applications.
COMPANY shall notify EMORY on behalf of the LICENSOR in writing of the countries in which COMPANY wishes additional patent applications
to be filed under the Licensed Patents, including but not limited to national phase filings and regional registrations. LICENSOR
shall, at COMPANY’s expense, promptly file such additional patent applications. LICENSOR may, at its own expense, file patent
applications in any country in which COMPANY elects not to file and such applications shall not be subject to any license granted
to COMPANY hereunder.

 

7.1.3        Reimbursement. If
COMPANY should fail to timely make reimbursement for patent expenses for any Licensed Patent, LICENSOR, in addition to any other
remedies under the Agreement, shall have no further obligation to Prosecute or Maintain such Licensed Patent(s). COMPANY, upon
[*****] written notice, may advise EMORY on behalf of the LICENSOR that it no longer wishes to pay expenses for Prosecution or
Maintenance of one or more Licensed Patents. LICENSOR may, at its sole option, elect to pay such expenses and, if so, such patents
or patent applications shall cease to be subject to any license granted to COMPANY hereunder.

 

7.1.4        Information to the COMPANY.
EMORY on behalf of the LICENSOR shall use reasonable efforts to provide COMPANY with copies of all patent correspondence relating
to the Licensed Patents. EMORY on behalf of the LICENSOR shall provide copies of all patent applications and all filings, correspondence
and other related documentation pertaining to prosecutorial matters arising from the patent prosecution activities, including,
but not limited to, all office actions, requests for examinations and restriction requirements.

 

    16 

     

    

 

7.2     Extension
of Licensed Patents. LICENSOR shall direct Prosecution and Maintenance of the Licensed Patents, including any extension to
the term of the Licensed Patents. COMPANY, at its expense, may request in writing at least [*****] before expiration of the Licensed
Patent that LICENSOR have the normal term of any Licensed Patents extended or restored under any country's procedure for extending
patent term. Royalties shall be payable until the end of the extended term of the patent. In the event that COMPANY does not elect
to extend a Licensed Patent, LICENSOR may, at its own expense, effect such extension and, if LICENSOR elects to pay such expenses,
such extended Licensed Patents shall not be subject to any license granted hereunder subsequent to its non-extended expiration
date.

 

Article
8.       INFRINGEMENT

 

8.1     The
Parties shall promptly notify each other of any suspected infringement of any Licensed Patents.

 

8.1.1      During the Term, COMPANY shall, at its expense,
have the right to enforce any Licensed Patents against such infringer and may defend any declaratory judgment action brought against
it alleging the invalidity of a Licensed Patent. COMPANY agrees to defend LICENSOR against any counterclaim brought against it
in such action. LICENSOR shall cooperate with reasonable requests from COMPANY in such effort, at COMPANY'S expense, including
being joined as a party to such action, if necessary. COMPANY shall reimburse LICENSOR for actual costs incurred, including reasonable
attorneys’ fees, as part of any action brought by COMPANY.

 

8.1.2      COMPANY shall use its best efforts to
terminate any suspected infringement of any Licensed Patents or resolve any other actual or potential claim(s) or cause(s) of
action without resorting to litigation, which may include negotiating and executing a sublicense agreement that complies with
the terms of this Agreement. COMPANY understands and agrees that any sublicense entered into under this Section must satisfy
all requirements of a sublicense as set forth in Section 2.5, including obtaining written approval from EMORY on behalf of
the LICENSOR. Before COMPANY commences an action with respect to any infringement or potential infringement or commences an
action filed by, or responds to an allegation raised by, a third party, it shall give careful consideration to the views and
the potential effects on the public interest in making its decision whether or not to sue or how to respond. LICENSOR shall
use reasonable efforts in accordance with their own policies and procedures to cooperate with COMPANY in connection with any
such remedial action undertaken by COMPANY under this Section, and COMPANY shall be responsible for any costs and expenses
incurred by LICENSOR associated with such cooperation.

 

    17 

     

    

 

8.1.3      COMPANY shall not enter into any settlement agreement,
voluntary dismissal, consent judgment, agreement pursuant to Section 8.1.2., or other voluntary final disposition in any action
regarding the Licensed Patents, without the express written consent of EMORY on behalf of LICENSOR, which shall not be unreasonably
withheld. For the avoidance of doubt, COMPANY acknowledges that it shall not be unreasonable for LICENSOR to withhold consent to
any settlement agreement, voluntary dismissal, consent judgment, agreement pursuant to Section 8.1.2., or other voluntary final
disposition in any action regarding the Licensed Patents that does not include a complete release of such party from all liability
or that contains or contemplates any payment by, or injunctive or equitable relief binding upon such party. Any amounts received
shall first be applied in satisfaction of the actual and reasonable costs and expenses incurred by COMPANY and any balance shall
be deemed to be proceeds of Sales of Licensed Products in the fiscal quarter received.

 

8.2     If
COMPANY fails, within [*****] after receiving notice of a potential infringement, to institute an action against such infringer
or notifies LICENSOR that it does not plan to institute such action, then LICENSOR shall have the right to do so at its own expense.
COMPANY shall cooperate with LICENSOR in such effort including being joined as a party to such action if necessary. LICENSOR shall
be entitled to retain all damages or costs awarded in such action. Should either LICENSOR or COMPANY be a party to a suit under
the provisions of this Article and thereafter elect to abandon such suit, the abandoning party shall give timely notice to the
other party who may, at its discretion, continue prosecution of such suit at its own expense.

 

Article
9.       LIMITED WARRANTY AND EXCLUSION OF WARRANTIES

 

9.1     Representation
by LICENSOR. Each of the entities comprising the LICENSOR represents and warrants that it has the right and authority to
enter into this Agreement and that, to the best of its knowledge, neither the execution of this Agreement nor the performance
of its obligations hereunder will constitute a breach of the terms and provisions of any other agreement to which it is a
party. EMORY represents that, to the best of its knowledge, as of the Effective Date, the LICENSOR is the owner of the
Licensed Technology and has the right to issue licenses to the same. LICENSOR does not warrant the validity of the Licensed
Patents licensed hereunder and makes no representation whatsoever with regard to the scope of the Licensed Patents or that
such Licensed Patents or Licensed Technology may be exploited by COMPANY or its Affiliates or Sublicensees without infringing
other patents.

 

    18 

     

    

 

 

9.2     Merchantability
and Exclusion of Warranties. COMPANY possesses the necessary expertise and skill in the technical areas pertaining to the Licensed
Products and Licensed Technology to make, and has made, its own evaluation of the capabilities, safety, utility and commercial
application of the Licensed Products and Licensed Technology. NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, COMPANY MAKES NO
REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, REGARDING THE RESULTS OF ITS EFFORTS TO DEVELOP, MANUFACTURE
OR COMMERCIALIZE ANY LICENSED PRODUCT. LICENSOR DOES NOT MAKE ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE LICENSED
TECHNOLOGY OR LICENSED PRODUCTS AND EXPRESSLY DISCLAIMS ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE AND
ANY OTHER IMPLIED WARRANTIES WITH RESPECT TO THE CAPABILITIES, SAFETY, UTILITY, OR COMMERCIAL APPLICATION OF THE LICENSED TECHNOLOGY
OR LICENSED PRODUCTS.

 

Article
10.       DAMAGES, INDEMNIFICATION AND INSURANCE

 

10.1  
No Liability. LICENSOR shall not be liable to COMPANY or COMPANY'S Affiliates, or customers and/or Sublicensees of COMPANY
or COMPANY’S Affiliates, for compensatory, special, incidental, indirect, consequential or exemplary damages resulting from
the manufacture, testing, design, labeling, use or sale of Licensed Products.

 

10.2   Indemnification.
COMPANY shall defend, indemnify, and hold harmless the Indemnitees, from and against any and all claims, demands, loss, liability,
expense, or damage (including reasonable investigative costs, court costs and attorneys' fees) (“Claims”) Indemnitees
may suffer, pay, or incur as a result of claims, demands or actions against any of the Indemnitees to the extent caused by or resulting
from, in whole or in part, COMPANY'S or COMPANY'S Affiliates, contractors, agents, or Sublicensees manufacture, testing, design,
use, Sale, or labeling of any Licensed Products or the use of any Licensed Technology or the use of any Licensed Product by any
third party, including any consumer or customer, except to the extent caused by the negligence or willful misconduct of LICENSOR,
and/or any of their Affiliates, and/or their respective contractors, agents or employees, including the Inventors. COMPANY'S obligations
under this Article shall survive the expiration or termination of this Agreement for any reason.

 

    19 

     

    

 

COMPANY agrees to provide attorneys reasonably
acceptable to LICENSOR to defend against such a claim. LICENSOR shall cooperate with COMPANY in any defense of such claim. COMPANY
shall not settle any such claims, demands or actions under this Section 10.2, without the express, prior written consent of LICENSOR,
which consent shall not be unreasonably withheld or delayed. COMPANY'S obligations under this Article shall survive the expiration
or termination of this Agreement for any reason.

 

10.3   Insurance.
Without limiting COMPANY'S indemnity obligations under the preceding paragraph, COMPANY shall, prior to any clinical trial or Sale
of any Licensed Product, cause to be in force a products liability insurance policy. Such policy shall:

 

		(i)	provide product liability coverage in an amount that is customary for the stage of development, but no less than [*****] per
occurrence;
		(ii)	insure Indemnitees for all claims, damages, and actions mentioned in Section 10.2 of this Agreement;
		(iii)	include contractual liability coverage for all liability which may be incurred by Indemnitees in connection with this Agreement;
		(iv)	include clinical trial coverage (if excluded from product liability coverage), COMPANY agrees to secure separate clinical trial
Errors & Omissions Liability coverage that meets all policy requirements as outlined in Section 10.3;
		(v)	require the insurance carrier to provide EMORY on behalf of the LICENSOR with no less than [*****] written notice of any change
in the terms or coverage of the policy or its cancellation; and
		(vi)	If written on a “claims made” basis, the Company agrees to provide coverage for ten years after the contract is
completed.

 

All insurance coverage required under this
Agreement shall be primary to any coverage carried by EMORY, CHILDREN’S, and UABRF, shall waive all rights of subrogation
against any additional insured and shall be placed with insurers whose A.M. Best’s rating is at least A-X.

 

As detailed in Section 2.5, COMPANY agrees
to require any Sublicensee under Section 2.5 of this Agreement to maintain insurance coverage consistent with this Section 10.3.

 

10.4   Notification.
COMPANY shall provide to EMORY on behalf of the LICENSOR prior to its first clinical trial or commercial Sale of any Licensed Product,
certificates of insurance evidencing the coverages required in section 10.3 above and adding each entity constituting the LICENSOR
as additional insureds.

 

    20 

     

    

 

10.5   Notice
of Claims. COMPANY shall promptly notify EMORY on behalf of the LICENSOR of all claims involving the Indemnitees and shall
advise EMORY of the amounts that might be needed to defend and pay any such claims. EMORY on behalf of the LICENSOR shall promptly
notify COMPANY of any and all claims brought to the LICENSOR’s attention relating to COMPANY’s indemnity obligations
under this Agreement.

 

Article
11.       CONFIDENTIALITY

 

11.1   Treatment
of Confidential Information. Except as otherwise provided hereunder, during the term of this Agreement and for a period of
[*****] thereafter:

 

		(i)	COMPANY and its Affiliates and Sublicensees shall retain in confidence and use only for purposes of this Agreement, any written
information and data supplied by LICENSOR under this Agreement and marked as proprietary;
		(ii)	LICENSOR shall retain in confidence and use only for purposes of this Agreement any written information and data supplied by
COMPANY under this Agreement and marked as proprietary.

 

For purposes of this Agreement, all such
information and data which a party is obligated to retain in confidence shall be called "Confidential Information."

 

11.2   Right
to Disclose. To the extent that it is reasonably necessary to fulfill its obligations or exercise its rights under this Agreement,
or any rights which survive termination or expiration hereof, each party may disclose Confidential Information to its Affiliates,
Sublicensees, consultants, outside contractors, governmental regulatory authorities and clinical investigators on condition that
such entities or persons agree:

 

		(i)	to keep the Confidential Information confidential for at least the same time periods and to the same extent as each party is
required to keep it confidential;
		(ii)	to use the Confidential Information only for such purposes as such parties are authorized to use it.

 

11.3   Release
from Restrictions. Each party or its Affiliates or Sublicensees may use or disclose Confidential Information to the government
or other regulatory authorities to the extent that such disclosure is reasonably necessary for the prosecution and enforcement
of patents, or to obtain or maintain any regulatory approval, including authorizations to conduct clinical trials, or commercially
market or obtain pricing approval of any Licensed Products, provided that such party is otherwise entitled to engage in such activities
under this Agreement.

 

    21 

     

    

 

The obligation not to disclose Confidential
Information shall not apply to any part of such Confidential Information that:

 

		(i)	is or becomes patented, published or otherwise part of the public domain, other than by unauthorized acts of the party obligated
not to disclose such Confidential Information (for purposes of this Article 11 the "receiving party") or its Affiliates
or Sublicensees in contravention of this Agreement;
		(ii)	is disclosed to the receiving party or its Affiliates or Sublicensees by a third party provided that such Confidential Information
was not obtained by such third party in violation of any legal obligation; or
		(iii)	prior to disclosure under this Agreement, was already in the possession of the receiving party, its Affiliates or Sublicensees,
provided that such Confidential Information was not obtained directly or indirectly from the other party under this Agreement;
or
		(iv)	results from research and development by the receiving party or its Affiliates or Sublicensees, independent of the disclosing
party’s Confidential Information; or
		(v)	is required by law to be disclosed by the receiving party, provided that the receiving party uses its best efforts to notify
the other party immediately upon learning of such requirement in order to give the other party reasonable opportunity to oppose
such requirement; or
		(vi)	COMPANY and EMORY on behalf of the LICENSOR agree in writing may be disclosed.

 

Article
12.       TERM AND TERMINATION

 

12.1.  Term.
Unless sooner terminated as otherwise provided in this Agreement, the term of this Agreement (“Term”) shall commence
on the Effective Date hereof and shall continue in full force and effect until the later of fifteen (15) years from the date of
the first commercial Sale on a country by country basis or the expiration of the last to expire of the Licensed Patents in that
country (“Expiration”).

 

12.2.  Termination.
EMORY, on behalf of LICENSOR, shall have the right to terminate this Agreement upon the occurrence of a material breach by COMPANY.
Without limitation, any one or more of the following shall each be deemed a material breach of this Agreement by COMPANY:

 

		12.2.1.	[*****]; or
		12.2.2.	[*****]; or
		12.2.3.	[*****]; or
		12.2.4.	[*****]; or
		12.2.5.	[*****]; or
		12.2.6.	[*****]; or
		12.2.7.	the breach by COMPANY of any other material term of this Agreement.

 

    22 

     

    

 

Notwithstanding the foregoing, if the Company
challenges the validity or enforceability of any Licensed Patent in a court or other governmental agency of competent jurisdiction,
this Agreement shall terminate immediately.

 

EMORY on behalf of the LICENSOR shall provide
COMPANY written notice describing the breach, which notice shall include EMORY’s intention to terminate the Agreement on
behalf of the LICENSOR. If COMPANY does not cure the breach within [*****] after receipt of such notice, this Agreement will terminate
immediately. If COMPANY disputes such breach in good faith by written notice to EMORY within the [*****] period, the matter will
be submitted to dispute resolution as described under Article 14. EMORY’s right to terminate shall be suspended until resolution
of the dispute. The procedures set forth in this Section 12.2 shall not prejudice LICENSOR’s right to receive royalties or
other sums due hereunder and shall not prejudice any cause of action or claim due to any breach or default by the COMPANY.

 

12.3.  Notice
of Bankruptcy. COMPANY must inform EMORY on behalf of the LICENSOR of its intention to file a voluntary petition in bankruptcy
or of another's intention to file an involuntary petition in bankruptcy to be received at least [*****] prior to filing such a
petition. If COMPANY files a petition of bankruptcy [*****].

 

12.4.  Failure
to Enforce. The failure of EMORY on behalf of the LICENSOR, at any time, or for any period of time, to enforce any of the provisions
of this Agreement, shall not be construed as a waiver of such provisions or as a waiver of the right of EMORY or the LICENSOR thereafter
to enforce each and every such provision of this Agreement.

 

12.5.  Termination
by COMPANY. COMPANY shall have the right to terminate this Agreement at its sole discretion upon [*****] written notice to
EMORY, on behalf of the LICENSOR. Such termination shall not relieve COMPANY of any obligations accruing prior to the date of termination,
including the payment of any amounts due to EMORY on behalf of the LICENSOR under this Agreement through the effective date of
such termination.

 

12.6.  Effect. If
this Agreement is terminated for any reason other than Expiration, COMPANY shall return, or at LICENSOR's direction, destroy,
all tangible materials (including plans, documents, samples, biological materials, models and the like) pertaining to the
Licensed Technology supplied to COMPANY by LICENSOR, retaining one archival copy in its corporate legal department as
required solely for compliance with any continuing obligations. Upon
termination of this Agreement for any reason, in the event LICENSOR requests in writing to COMPANY, COMPANY shall provide
LICENSOR, at LICENSOR’s sole cost and expense, [*****]. In the event this Agreement terminates or expires for any
reason except material breach by COMPANY, LICENSOR shall not [*****] for a period of two (2) years without the written
consent of COMPANY. For clarity, in the event this Agreement terminates due to a material breach by COMPANY, LICENSOR shall
have the right to [*****] without any delay by COMPANY. Upon termination of this Agreement, COMPANY shall cease
manufacturing, processing, producing, using, importing or Selling Licensed Products; provided, however, that COMPANY may
continue to Sell in the ordinary course of business for a period of [*****] reasonable quantities of Licensed Products which
are fully manufactured and in COMPANY’s normal inventory at the date of termination if (a) all monetary obligations of
COMPANY to LICENSOR have been satisfied and (b) royalties on such sales are paid to LICENSOR in the amounts and in the manner
provided in this Agreement. However, nothing herein shall be construed to release either party of any obligation which
matured prior to the effective date of such termination. 

 

    23 

     

    

 

12.7.  Regulatory
Information: In the event LICENSOR [*****], COMPANY shall [*****] the right to [*****]. Should COMPANY [*****] during the term
of this Agreement, COMPANY may [*****] for development, use or sale of Licensed Product(s).

 

Article
13.       ASSIGNMENT

 

COMPANY may grant, transfer, convey, or
otherwise assign any or all of its rights and obligations under this Agreement in conjunction with (i) the transfer of all, or
substantially all, of the business interests of COMPANY or (ii) any merger or acquisition or business combination resulting in
a change of control of COMPANY. Except as otherwise permitted under this Agreement, LICENSOR's written consent, which shall not
be unreasonably withheld, shall be required prior to any other assignment of COMPANY'S rights or obligations under this Agreement.
This Agreement shall be assignable by each entity that comprises the LICENSOR to any other nonprofit corporation affiliated with
EMORY, CHILDREN’S, or UABRF upon prior written notice to COMPANY.

 

Article
14.        Dispute Resolution

 

14.1.  Negotiation.
Any dispute related to this License Agreement shall be settled in accordance with the procedures specified in this Section.
COMPANY and EMORY on behalf of the LICENSOR agree to attempt to settle any claim or controversy arising out of this Agreement
through consultation and negotiation in good faith and spirit of mutual cooperation. Any dispute between the parties relating
to this Agreement will first be submitted in writing to a senior executive of COMPANY and EMORY on behalf of the LICENSOR
(the “Dispute Notice”), who will promptly meet and confer in an effort to resolve such dispute. Any agreed
decisions of the executives will be final and binding on the parties. All negotiations pursuant to this Section are
confidential and shall be treated as compromise and settlement negotiations for purposes of applicable rules of
evidence.

 

14.2.  Mediation.
If the parties are unable to resolve any dispute by negotiation within [*****] of the Dispute Notice, then either party may initiate
mediation upon written notice to the other party demanding mediation (the “Mediation Notice”), whereupon the dispute
will be mediated by a mutually acceptable mediator to be chosen within [*****] after the Mediation Notice. The parties will share
the costs of the mediator equally. If the parties cannot agree upon selection of a mediator within [*****] of the notice, then
upon request of either party, the AAA shall appoint the mediator. Mediation shall take place in [*****] and shall proceed under
the then current American Arbitration Association Model Commercial Mediation Procedures to the extent that the Model Procedure
does not conflict with provisions of this article.

 

14.3.  Arbitration.
Any dispute which has not been resolved by negotiation or mediation as described above within [*****] of the Dispute Notice, shall
be settled by arbitration. The Arbitrators shall not have the ability to determine the validity or enforceability of any Licensed
Patent. Arbitration shall be conducted under the Commercial Arbitration Rules of the American Arbitration Association by three
arbitrators, one to be appointed by EMORY on behalf of the LICENSOR, one to be appointed by COMPANY, and one to be appointed by
the two arbitrators appointed by EMORY and COMPANY. Arbitration shall take place in [*****], and the decision of the arbitrators
shall be enforceable, but not appealable, in any court of competent jurisdiction.

 

14.4.  Costs.
The fees and expenses, but not attorney’s fees, incurred in connection with any mediation or arbitration shall be borne by
the party initiating the mediation or arbitration proceeding (or equally by both parties if both parties jointly initiate such
proceeding) subject to reimbursement by the party which does not prevail in such proceeding promptly upon the termination thereof
in the event that the party initiating such proceeding is the prevailing party.

 

14.5.  Continued
Obligations. Each party shall continue to perform its undisputed obligations under this Agreement, including payments due,
pending final resolution of any dispute arising out of or relating to this Agreement; provided, however that a party may suspend
performance during any period in which the other party fails to perform its undisputed obligations.

 

    24 

     

    

       

Article
15.       MISCELLANEOUS

 

15.1   Export
Controls. COMPANY acknowledges that Licensed Products and Licensed Technology may be subject to United States laws and regulations
controlling the export of technical data, biological materials, chemical compositions, computer software, laboratory prototypes
and other commodities and that LICENSOR's obligations under this Agreement are contingent upon compliance with applicable United
States export laws and regulations. The transfer of technical data and commodities may require a license from the cognizant agency
of the United States government or written assurances by COMPANY that COMPANY shall not export data or commodities to certain foreign
countries without the prior approval of certain United States agencies. EMORY on behalf of the LICENSOR neither represents that
an export license shall not be required nor that, if required, such export license shall issue.

 

15.2   Legal
Compliance. COMPANY shall comply with all laws and regulations relating to its manufacture, processing, producing, using, importing
Selling, labeling or distribution of Licensed Products and Licensed Technology and shall not take any action which would cause
LICENSOR or COMPANY to violate any laws or regulations.

 

15.3   Independent
Contractor. COMPANY'S relationship to LICENSOR shall be that of a licensee only. COMPANY shall not be the agent of LICENSOR
and shall have no authority to act for, or on behalf of, LICENSOR in any matter. Persons retained by COMPANY as employees or agents
shall not, by reason thereof, be deemed to be employees or agents of LICENSOR.

 

15.4   Patent
Marking. COMPANY shall mark Licensed Products Sold in the United States with United States patent numbers. Licensed Products
manufactured or Sold in other countries shall be marked in compliance with the applicable intellectual property laws in force in
such foreign countries.

 

15.5   Use
of Names. COMPANY shall obtain the prior written approval of the applicable LICENSOR or its Affiliate for the use of its trade
name, trademark, service marks, or other protectable indicia prior to making use of its name for any purpose, except as required
by law. Each of the entities making up LICENSOR shall obtain the prior written approval of COMPANY prior to making use of its or
its Affiliates’ Trade name, trademark, service marks, or other protectable indicia for any purpose, except as required by
law. As an exception to the foregoing, both COMPANY and each of the entities making up LICENSOR shall have the right to publicize
the existence of this Agreement; however, neither COMPANY nor LICENSOR shall disclose the terms and conditions of this Agreement
without the other party’s consent, except as required by law.

 

    25 

     

    

 

15.6   Place
of Execution. This Agreement and any subsequent modifications or amendments hereto shall be deemed to have been executed in
the State of Georgia, U.S.A.

 

15.7   Governing
Law. This Agreement and all amendments, modifications, alterations, or supplements hereto, and the rights of the parties hereunder,
shall be construed under and governed by the laws of the State of Georgia and the United States of America.

 

15.8   Venue.
Only courts in the State of Georgia, U.S.A., shall have jurisdiction to hear and decide any controversy or claim between the parties
arising under or relating to this Agreement.

 

15.9   Entire
Agreement. This Agreement constitutes the entire agreement between LICENSOR and COMPANY with respect to the subject matter
hereof and shall not be modified, amended or terminated, except as herein provided or except by another agreement in writing executed
by the parties hereto.

 

15.10 Survival.
Articles 3, 4, 5, 9, 10, 11, 12.6, 12.7, 14, and 15 shall survive termination of this Agreement for any reason.

 

15.11 Severability.
All rights and restrictions contained herein may be exercised and shall be applicable and binding only to the extent that they
do not violate any applicable laws and are intended to be limited to the extent necessary so that they will not render this Agreement
illegal, invalid or unenforceable. If any provision or portion of any provision of this Agreement, not essential to the commercial
purpose of this Agreement, shall be held to be illegal, invalid or unenforceable by a court of competent jurisdiction, it is the
intention of the parties that the remaining provisions or portions thereof shall constitute their agreement with respect to the
subject matter hereof, and all such remaining provisions, or portions thereof, shall remain in full force and effect. To the extent
legally permissible, any illegal, invalid or unenforceable provision of this Agreement shall be replaced by a valid provision which
shall implement the commercial purpose of the illegal, invalid, or unenforceable provision. In the event that any provision essential
to the commercial purpose of this Agreement is held to be illegal, invalid or unenforceable and cannot be replaced by a valid provision
which will implement the commercial purpose of this Agreement, this Agreement and the rights granted herein shall terminate.

 

15.12 Force
Majeure. Any delays in, or failure of performance of any party to this Agreement, shall not constitute a default hereunder,
or give rise to any claim for damages, if and to the extent caused by occurrences beyond the control of the party affected, including,
but not limited to, acts of God, strikes or other concerted acts of workmen, civil disturbances, fires, floods, explosions, riots,
war, rebellion, sabotage, acts of governmental authority or failure of governmental authority to issue licenses or approvals which
may be required.

 

15.13 Counterparts. This
Agreement may be executed by facsimile and in counterparts, each of which is deemed an original, but all of which together
shall constitute one and the same instrument

 

    26 

     

    

 

Article
16.       NOTICES

 

All notices, statements, and reports required
to be given by one party to the other shall be in writing. Progress and Royalty reports required under Article 4 may be delivered
electronically with a copy to OTT-Legal@emory.edu.

 

Except for progress and royalty reports
required under Article 4, all reports shall be hand delivered, sent by private overnight mail service, or sent by registered or
certified U.S. mail, postage prepaid, return receipt requested and addressed as follows:

 

	If to LICENSOR:	Emory University
	 	Office of Technology Transfer
	 	1599 Clifton Rd., 4th Floor
	 	Atlanta, Georgia 30322
	 	ATTN: Director
	 	Facsimile: (404) 727-1271
	 
	With copies to:	Children’s Healthcare of Atlanta
	 	Attn: Marie-Christine Reames
	 	Office of Technology Transfer
	 	1687 Tullie Circle NE,
	 	Atlanta, Georgia 30329
	 	Facsimile: (404) 785-9470
	 
	 	UAB Research Foundation
	 	701 20th Street South, AB 770
	 	Birmingham, Alabama 35233
	 	(1720 2nd Avenue South, AB 770
	 	Birmingham, AL 35294)
	 	Attention Executive Director
	 	 
	If to COMPANY:	Incysus, Ltd.
	 	Clarendon House
	 	2 Church Street
	 	Hamilton, HM11 Bermuda
	 	 
	With copies to:	Jill E. Anderson
	 	Moses & Singer LLP
	 	The Chrysler Building
	 	405 Lexington Avenue
	 	New York, NY 10174
	 	Fascimile: (917) 206-4377

 

    27 

     

    

 

Such notices or other communications shall
be effective upon receipt by an employee, agent or representative of the receiving party authorized to receive notices or other
communications sent or delivered in the manner set forth above. Either party hereto may change the address to which notices to
such party are to be sent by giving notice to the other party at the address and in the manner provided above. Any notice may be
given, in addition to the manner set forth above by facsimile provided that the party giving such notice obtains acknowledgement
by facsimile that such notice has been received by the party to be notified. Notice made in this manner shall be deemed to have
been given when such acknowledgement has been transmitted.

 

[REMAINDER OF PAGE
LEFT INTENTIONALLY BLANK]

 

    28 

     

    

 

IN WITNESS WHEREOF, Each of the LICENSOR and COMPANY
have caused this Agreement to be signed by their duly authorized representatives as of the day and year indicated below.

 

	EMORY UNIVERSITY	 	INCYSUS, LTD.
	 	 	 	 	 
	By:	/s/
    Authorized Signatory	 	By:	/s/
    William Ho
	 	 	 	Name:	William
    Ho
	 	 	 	Title:
    	President
    and Chief Executive Officer
	Date:
     	June
    7, 2016	 	 	 

	 	 	 	 	 
	LIC.__.___	 	Date:	June
    10, 2016

 

	CHILDREN’S
    HEALTHCARE OF ATLANTA, INC.:	 
	 	 
	By:	/s/
    Authorized Signatory	 
	 	 
	 	 
	Date	June
    7, 2016	 
	 	 
	THE
    UAB RESEARCH FOUNDATION	 
	 	 
	By:	/s/
    Authorized Signatory	 
	 	 
	Date: 	June
    7, 2016	 

 

    29 

     

    

 

       

APPENDIX
A

 

COMPANY’S DEVELOPMENT PLAN 

 

[*****]

 

     

     

    

 

APPENDIX
B

 

LICENSED PATENTS

 

[*****]

     

     

    

 

APPENDIX
C

 

U. S. GOVERNMENT LICENSE(S)

 

[*****]

 

     

     

    

 

APPENDIX
D

 

RUNNING ROYALTY PERCENTAGES

 

	Cumulative Annual Net Sales less than [*****]	Percentage of Net Selling Price
	Countries in which Licensed Patents exist	[*****]
	Countries in which Licensed Patents do not exist	 [*****]
	 
	Cumulative Annual Net Sales over [*****] and below [*****]	 Percentage of Net Selling Price
	Countries in which Licensed Patents exist	 [*****]
	Countries in which Licensed Patents do not exist	 [*****]
	 
	Cumulative Annual Net Sales over [*****]	Percentage of Net Selling Price
	Countries in which Licensed Patents exist	 [*****]
	Countries in which Licensed Patents do not exist	 [*****]

 

     

     

    

 

APPENDIX
E

 

MINIMUM ROYALTIES

 

 

	Calendar Year after First Sale	 Minimum Royalty
	Year 3 (3rd calendar year following First
    Sale)	$500,000
	Year 4	 $1,000,000
	Year 5 and subsequent years	 $1,500,000

 

For clarity, the above minimum royalties shall only be payable
should pivotal results demonstrate the Licensed [*****].

 

     

     

    

 

APPENDIX
F

 

MILESTONES

 

	Milestone
    Event	 	Milestone
    Payment
	 	 	 
	a) 	[*****]	 	[*****]
	b) 	[*****]	 	[*****]
	 	 	 
	c)	[*****]	 	[*****]
	d) 	[*****]	 	[*****]
	 	 	 
	e) 	[*****]	 	[*****]
	f) 	[*****]	 	[*****]

 

     

     

    

 

APPENDIX
G

 

LICENSE MAINTENANCE FEES

 

	Effective
    Date Anniversary	 	License
    Maintenance Fee
	Fourth
    Anniversary	 	$
    250,000
	Fifth
    Anniversary	 	$
    500,000
	Sixth
    and Each Subsequent Anniversary	 	$
    1,000,000

 

     

     

    

 

APPENDIX
H

 

DEVELOPMENT MILESTONES AND DATES

 

 [*****]

 

     

     

    

 

APPENDIX
I

 

List of Low and Low Middle Income Countries

 

	1.	Afghanistan	South Asia	Low income
	2.	Bangladesh	South Asia	Low income
	3.	Benin	Sub-Saharan Africa	Low income
	4.	Burkina Faso	Sub-Saharan Africa	Low income
	5.	Burundi	Sub-Saharan Africa	Low income
	6.	Cambodia	East Asia & Pacific	Low income
	7.	Central African Republic	Sub-Saharan Africa	Low income
	8.	Chad	Sub-Saharan Africa	Low income
	9.	Comoros	Sub-Saharan Africa	Low income
	10.	Congo, Dem. Rep.	Sub-Saharan Africa	Low income
	11.	Eritrea	Sub-Saharan Africa	Low income
	12.	Ethiopia	Sub-Saharan Africa	Low income
	13.	Gambia, The	Sub-Saharan Africa	Low income
	14.	Guinea	Sub-Saharan Africa	Low income
	15.	Guinea-Bissau	Sub-Saharan Africa	Low income
	16.	Haiti	Latin America & Caribbean	Low income
	17.	Kenya	Sub-Saharan Africa	Low income
	18.	Korea, Dem. Rep.	East Asia & Pacific	Low income
	19.	Liberia	Sub-Saharan Africa	Low income
	20.	Madagascar	Sub-Saharan Africa	Low income
	21.	Malawi	Sub-Saharan Africa	Low income
	22.	Mali	Sub-Saharan Africa	Low income
	23.	Mozambique	Sub-Saharan Africa	Low income
	24.	Myanmar	East Asia & Pacific	Low income
	25.	Nepal	South Asia	Low income
	26.	Niger	Sub-Saharan Africa	Low income
	27.	Rwanda	Sub-Saharan Africa	Low income
	28.	Sierra Leone	Sub-Saharan Africa	Low income
	29.	Somalia	Sub-Saharan Africa	Low income
	30.	Tajikistan	Europe & Central Asia	Low income
	31.	Tanzania	Sub-Saharan Africa	Low income
	32.	Togo	Sub-Saharan Africa	Low income
	33.	Uganda	Sub-Saharan Africa	Low income
	34.	Zimbabwe	Sub-Saharan Africa	Low income
	35.	Armenia	Europe & Central Asia	Lower middle income
	36.	Bhutan	South Asia	Lower middle income
	37.	Bolivia	Latin America & Caribbean	Lower middle income
	38.	Cameroon	Sub-Saharan Africa	Lower middle income
	39.	Cabo Verde	Sub-Saharan Africa	Lower middle income
	40.	Congo, Rep.	Sub-Saharan Africa	Lower middle income
	41.	Côte d'Ivoire	Sub-Saharan Africa	Lower middle income
	42.	Djibouti	Middle East & North Africa	Lower middle income

 

     

     

    

 

	43.	Egypt, Arab Rep.	Middle East & North Africa	Lower middle income
	44.	El Salvador	Latin America & Caribbean	Lower middle income
	45.	Georgia	Europe & Central Asia	Lower middle income
	46.	Ghana	Sub-Saharan Africa	Lower middle income
	47.	Guatemala	Latin America & Caribbean	Lower middle income
	48.	Guyana	Latin America & Caribbean	Lower middle income
	49.	Honduras	Latin America & Caribbean	Lower middle income
	50.	India	South Asia	Lower middle income
	51.	Indonesia	East Asia & Pacific	Lower middle income
	52.	Kiribati	East Asia & Pacific	Lower middle income
	53.	Kosovo	Europe & Central Asia	Lower middle income
	54.	Kyrgyz Republic	Europe & Central Asia	Lower middle income
	55.	Lao PDR	East Asia & Pacific	Lower middle income
	56.	Lesotho	Sub-Saharan Africa	Lower middle income
	57.	Mauritania	Sub-Saharan Africa	Lower middle income
	58.	Micronesia, Fed. Sts.	East Asia & Pacific	Lower middle income
	59.	Moldova	Europe & Central Asia	Lower middle income
	60.	Mongolia	East Asia & Pacific	Lower middle income
	61.	Morocco	Middle East & North Africa	Lower middle income
	62.	Nicaragua	Latin America & Caribbean	Lower middle income
	63.	Nigeria	Sub-Saharan Africa	Lower middle income
	64.	Pakistan	South Asia	Lower middle income
	65.	Papua New Guinea	East Asia & Pacific	Lower middle income
	66.	Paraguay	Latin America & Caribbean	Lower middle income
	67.	Philippines	East Asia & Pacific	Lower middle income
	68.	Samoa	East Asia & Pacific	Lower middle income
	69.	São Tomé and Principe	Sub-Saharan Africa	Lower middle income
	70.	Senegal	Sub-Saharan Africa	Lower middle income
	71.	Solomon Islands	East Asia & Pacific	Lower middle income
	72.	South Sudan	Sub-Saharan Africa	Lower middle income
	73.	Sri Lanka	South Asia	Lower middle income
	74.	Sudan	Sub-Saharan Africa	Lower middle income
	75.	Swaziland	Sub-Saharan Africa	Lower middle income
	76.	Syrian Arab Republic	Middle East & North Africa	Lower middle income
	77.	Timor-Leste	East Asia & Pacific	Lower middle income
	78.	Ukraine	Europe & Central Asia	Lower middle income
	79.	Uzbekistan	Europe & Central Asia	Lower middle income
	80.	Vanuatu	East Asia & Pacific	Lower middle income
	81.	Vietnam	East Asia & Pacific	Lower middle income
	82.	West Bank and Gaza	Middle East & North Africa	Lower middle income
	83.	Yeman, Rep	Middle East & North Africa	Lower middle income
	84.	Zambia	Sub-Saharan Africa	Lower middle income

 

     

     

    

 

APPENDIX
J

 

Template
for Progress Reports

 

COMPANY

Address

City, State, Zip

 

Progress Report covering the period [January-June,
YR or July-December, YR] for the License between COMPANY, Emory University, Children’s Hospital of Atlanta and
UAB Research Foundation dated          ________________, Emory Ref. LIC.___._____

 

As required under Article 4 of the above-referenced
license agreement, the following details the progress made during the reporting period in commercializing the licensed technology.

 [*****]Exhibit 10.15

 

Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information
marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful
if publicly disclosed.

 

Second Amendment to Exclusive License
Agreement between Emory University (“Emory”), Children’s Healthcare of Atlanta, Inc. (“CHOA”), The
UAB Research Foundation (“UABRF”) and Incysus , Ltd. 

 

This Second Amendment
to Exclusive License Agreement (this “Second Amendment”) is made effective as of the date of the last signature
of the Parties (as evidenced below their signatures on the signature page) (the “Second Amendment Effective Date”)
by and between Emory University, Children’s Healthcare of Atlanta, Inc., The UAB Research Foundation (hereinafter together
the “LICENSOR”) and Incysus Therapeutics, Inc. (“COMPANY”). COMPANY and Licensor may be each
individually referred to as a party and collectively, the parties (“Party” or “Parties”).

 

RECITALS

 

WHEREAS, Licensor and
Incysus, Ltd. previously entered into that certain Exclusive License Agreement dated effective as of June 10th, 2016
(“Agreement”), as amended on October 7th, 2017;

 

WHEREAS, on May 7,
2018, Incysus, Ltd. changed its name and incorporation to Incysus Therapeutics, Inc. in the State of Delaware; and

 

WHEREAS, the Parties
wish to amend the Agreement to replace Incysus, Ltd with Incysus Therapeutics, Inc. as a party to the Agreement, to reflect Incysus’
new corporate information in the Agreement, to modify Section 15.12 and to revise the license maintenance fees under Appendix G
of the Agreement.

 

NOW, THEREFORE, for
good and valuable consideration, the Parties agree to amend the Agreement as follows:

 

AGREEMENT

 

1.       All
capitalized terms used herein shall bear the meaning ascribed to them in Article 1, DEFINITIONS of the Agreement unless otherwise
defined herein.

 

2.       Incysus
Therapeutics, Inc., or any other name by which Incysus Therapeutics, Inc. may be titled, having a place of business at 79 Madison
Avenue, New York, NY 10016, shall replace Incysus, Ltd. as a party to the Original Agreement.

 

    1.

     

    

 

3.       Delete
Section 15.12 in its entirety and replace with the following:

 

Section 15.12 Force Majeure.
No Party shall be liable or responsible to the other Party, nor be deemed to have defaulted under or breached this Agreement,
for any failure or delay in fulfilling or performing any term of this Agreement (except for any obligations to make
previously owed payments to the other Party hereunder) when and to the extent such failure or delay is caused by or results
from acts beyond the impacted Party’s (“Impacted Party”) reasonable control, including, without
limitation, the following force majeure events (“Force Majeure Event(s)”) that frustrates the purpose of
this Agreement: (a) acts of God; (b) flood, fire, earthquake or explosion; (c) war, invasion, hostilities (whether war is
declared or not), terrorist threats or acts, riot or other civil unrest; (d) government order or law; (e) actions, embargoes
or blockades in effect on or after the date of this Agreement; (f) action by any governmental authority; (g) national or
regional emergency; (h) strikes, labor stoppages or slowdowns or other industrial disturbances; (i) epidemic, pandemic or
similar influenza or bacterial infection (which is defined by the United States Center for Disease Control as virulent human
influenza or infection that may cause global outbreak, or pandemic, or serious illness); (j) emergency state; (k) shortage of
adequate medical supplies and equipment; (l) shortage of power or transportation facilities; and (m) other similar events
beyond the reasonable control of the Impacted Party.

 

The Impacted Party
shall provide the other Party with written notice of a Force Majeure Event within [*****] after the Impacted Party, acting in good
faith and using reasonable diligence, reasonably determines that a Force Majeure Event will impact its operations to the extent
that its performance under this Agreement will be delayed or frustrated, including with such notice the Impacted Party’s
reasonable estimate of the duration of the Force Majeure Event and the expected time of performance by the Impacted Party, if any.
The Impacted Party shall use diligent efforts to end the failure or delay and ensure the effects of such Force Majeure Event are
minimized and shall resume its performance under the Agreement as soon as reasonably practicable after the removal of the cause
of the Force Majeure Event. In addition to such other rights and remedies as may be available to Licensor, if Company is the Impacted
Party, Licensor shall have the right to immediately terminate this Agreement by providing written notice thereof to Licensor if
any Force Majeure Event continues, or is expected to continue, for more than [*****].

 

4.       Replace
APPENDIX G, LICENSE MAINTENANCE FEES. in its entirety with the following:

 

APPENDIX G

 

LICENSE MAINTENANCE FEES

 

	Effective Date Anniversary	License Maintenance Fee
	78th Month Anniversary (December 10, 2022)	$250,000
	90th Month Anniversary (December 10, 2023)	$500,000
	Eighth and Each Subsequent Anniversary	$1,000,000

 

5.       All
other terms and conditions of the Agreement shall remain in full force and effect.

 

    2.

     

    

 

IN WITNESS WHEREOF, Emory and Company have
each caused its duly authorized representative to execute this Second Amendment, effective as of the date written above.

 

	EMORY:	 	COMPANY:
	Emory
    University	 	Incysus Therapeutics, Inc.
		 	 
	By:	/s/
    Authorized Signatory 	 	By:	/s/
    William Ho
	 	 	Name:
    William Ho
	 	 	Title:
    President & CEO

 

	Date Signed:	 07/14/20	 	Date Signed: 	07/14/20

 

	CHILDREN’S HEALTHCARE OF ATLANTA, INC.:	 
	 	 
	By:	/s/ Authorized Signatory	 

 

	Date Signed:	07/14/20	 

 

	THE UAB RESEARCH FOUNDATION:
	 
	By:	 /s/ Authorized Signatory	 

 

	Date Signed:	 07/14/20	 

 

    3.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00315-of-00352.parquet"}]]